Get the Stockscreener App
28.75
1.81%
-0.53
After Hours:
28.74
-0.01
-0.03%
Maplight Therapeutics Inc stock is traded at $28.75, with a volume of 164.14K.
It is down -1.81% in the last 24 hours and down -10.52% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$29.28
Open:
$29.54
24h Volume:
164.14K
Relative Volume:
0.64
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-7.7391
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
+0.07%
1M Performance:
-10.52%
6M Performance:
+105.50%
1Y Performance:
+0.00%
1-Day Range:
$28.30
$29.97
1-Week Range:
$25.21
$29.97
52-Week Range:
$12.24
$33.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
28.75 | 1.33B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Craig-Hallum initiates coverage of MapLight Therapeutics (MPLT) with buy recommendation - MSN
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock By Investing.com - Investing.com Australia
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock - Investing.com UK
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock By Investing.com - Investing.com Australia
MapLight Therapeutics CMO Foff sells $126,639 in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 By Investing.com - Investing.com Canada
MapLight Therapeutics CMO Foff sells $126,639 in stock By Investing.com - Investing.com South Africa
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 - Investing.com India
MapLight Therapeutics (MPLT) CSO sells 721 shares in planned trade - Stock Titan
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2026 - MarketBeat
MapLight Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
MapLight plans two New York investor events with live webcasts - Stock Titan
Maplight Therapeutics Insider Sold Shares Worth $1,427,594, According to a Recent SEC Filing - Moomoo
Maplight Therapeutics Insider Sold Shares Worth $1,024,719, According to a Recent SEC Filing - Moomoo
Maplight Therapeutics Insider Sold Shares Worth $388,177, According to a Recent SEC Filing - Moomoo
5AM Venture Management, LLC's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):